GBP2: A Potential Drug Target for Various Diseases (G2634)

Target Name: GBP2

NCBI ID: G2634

GBP2

GBP2: A Potential Drug Target for Various Diseases

Glycophospholipase (GBP) 2 (GBP2) is a protein that is expressed in various tissues throughout the body. It is a key enzyme in the lipid metabolism pathway, which is involved in the production and breakdown of lipids. GBP2 is a potent enzyme that is involved in the regulation of lipid metabolism, and it is a potential drug target for various diseases.

GBP2 is a member of the Glycophospholipase (GP) family, which includes a variety of enzymes that are involved in the regulation of lipid metabolism. The GP family is characterized by the presence of a catalytic active site, a hydrophobic core, and a flexible hydrophobic arm. This structural feature allows the GP enzymes to catalyze a wide range of lipid reactions, including the hydrolysis of phospholipids and the addition of phosphate groups to other molecules.

GBP2 is widely expressed in various tissues throughout the body, including muscle, heart, liver, and kidney. It is a key enzyme in the lipid metabolism pathway, as it is involved in the breakdown of fatty acids from dietary lipids and the synthesis of triacylglycerols from these fatty acids. GBP2 is also involved in the regulation of lipid transport and storage, as well as in the regulation of cellular signaling pathways.

GBP2 has been shown to be involved in a variety of diseases and disorders. For example, it has been shown to be involved in the development and progression of atherosclerosis, a condition in which plaque builds up in the arteries and can cause heart attack or stroke . GBP2 has also been shown to be involved in the development of obesity and type 2 diabetes, as well as in the regulation of cellular signaling pathways that are involved in these diseases.

In addition to its involvement in diseases and disorders, GBP2 is also a potential drug target. The development of new drugs that target GBP2 and its downstream targets may provide new treatments for a variety of diseases. For example, inhibitors of GBP2 have been shown to be effective in treating a variety of conditions, including heart failure, obesity, and diabetes.

In conclusion, GBP2 is a protein that is widely expressed in various tissues throughout the body and is involved in the regulation of lipid metabolism. Its catalytic active site and flexible hydrophobic arms make it a potential drug target for various diseases. Further research is needed to fully understand the role of GBP2 in disease and to develop new treatments for GBP2-related conditions.

Protein Name: Guanylate Binding Protein 2

Functions: Interferon (IFN)-inducible GTPase that plays important roles in innate immunity against a diverse range of bacterial, viral and protozoan pathogens (PubMed:31091448). Hydrolyzes GTP to GMP in 2 consecutive cleavage reactions, but the major reaction product is GDP (PubMed:8706832). Following infection, recruited to the pathogen-containing vacuoles or vacuole-escaped bacteria and acts as a positive regulator of inflammasome assembly by promoting the release of inflammasome ligands from bacteria (By similarity). Acts by promoting lysis of pathogen-containing vacuoles, releasing pathogens into the cytosol (By similarity). Following pathogen release in the cytosol, promotes recruitment of proteins that mediate bacterial cytolysis: this liberates ligands that are detected by inflammasomes, such as lipopolysaccharide (LPS) that activates the non-canonical CASP4/CASP11 inflammasome or double-stranded DNA (dsDNA) that activates the AIM2 inflammasome (By similarity). Confers protection to the protozoan pathogen Toxoplasma gondii (By similarity). Independently of its GTPase activity, acts as an inhibitor of various viruses infectivity, such as HIV-1, Zika and influenza A viruses, by inhibiting FURIN-mediated maturation of viral envelope proteins (PubMed:31091448)

The "GBP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GBP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets